Drug profile · INN
lenacapavir
SUNLENCA
- US status
- approved
- Patents linked
- 0
- News articles
- 2
Quick answer
lenacapavir (SUNLENCA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Related news
FDA Grants Priority Review for Gilead's Bictegravir Plus Lenacapavir HIV Treatment Combination
Gilead Sciences receives FDA priority review for novel once-daily HIV treatment combining bictegravir and lenacapavir, potentially the smallest single-tablet regimen.
FDA Approves Gilead's Long-Acting HIV Treatment for Bi-Monthly Dosing
Gilead's long-acting HIV treatment has received FDA approval for bi-monthly dosing, providing patients with a more convenient and effective management option.
Frequently asked questions
What is lenacapavir?
lenacapavir (SUNLENCA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for lenacapavir?
SUNLENCA is a marketed brand name for lenacapavir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lenacapavir?
lenacapavir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.